- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03778268
Sentinel Lymph Node Mapping In Cervical Cancer (SLNMICC)
Comparing the Diagnostic Value of Different Lymph Node Tracing Methods in Detecting Sentinel Lymph Node Metastasis in Early Cervical Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Quality Control The investigators' quality assurance plan is as follows: A. Once the plan has been approved, it cannot be modified at will. If special circumstances such as difficulty in implementation are found after the start of the study, the proposal may be revised or supplemented by the discussion of the research group and the project leader, and the revised content shall be recorded in writing.
The program change process is as follows:
- Identify the problems and understand the necessary to change the plan;
- Convene the main members of the research team and the project leader to discuss and propose solutions;
- Revise the plan and update the version number, fill out the "Program Description";
- The revised plan and the "Revision of the Plan" need to be signed by the person in charge of the project. If necessary, they must be submitted to the ethics committee for approval or filing; if approved, the revised plan can be implemented.
B. In order to ensure that the research personnel have sufficient qualifications to undertake specific research work, the research personnel should at least complete the following training before the project starts:
- Research object protection and ethical requirements;
- Study protocols and related standard operating procedures (tracer injection methods, use of near-infrared fluorescent vascular imagers, and pathology);
- Case Report Form and gauge filling instructions (form entry criteria, surgical record methods, etc.);
- Clinical research project implementation considerations (such as research object screening, enrollment, data collection process); Project-related training should be carried out throughout the research process. The project leader and project coordinator can increase the training content according to the situation, such as training on weak links in the test, training on updating programs and various causes.
Data Management A. Case report form design The researcher is responsible for drafting the research case report form. B. Data Entry and Data Verification According to the final version of CRF, the project database is built using software. The data entry and verification is carried out by a dedicated person.
Statistical Analysis A. Statistical Analysis Plan and Statistical Software After the trial protocol is determined, the statistical professors and the main investigators are responsible for developing a statistical analysis plan. The statistical analysis software uses SAS® 9.2 software (software installation point authorization number: 11202165).
B. Calculation and reasoning of sample size The sample size is calculated using PASS11 software; the sample size is estimated based on the negative prediction value of the previous study, and the negative prediction value of SLNs is expected to be 90%; the allowable error is 2% (the range of the confidence interval is 88% to 92%). When the significant level is 0.05, 914 cases are needed to be studied. Considering the detection rate of 80% of SLNs, a total of 1143 cases are expected to be studied.
C. Statistical Analysis Methods General principle Using a two-sided test, a P value of less than 0.05 would be considered statistically significant.
The quantitative indicators will calculate the mean, standard deviation, median, minimum, maximum, lower quartile (Q1), upper quartile (Q3), and the classification indicators will describe the number of cases and percentages.
Comparison of clinicopathological features (age, body mass index, pathological type, tumor stage, grading, maximum tumor diameter, invasive myometrial depth, lymphatic vascular infiltration, and tracer method) for SLNs and undetected SLNs will be based on the type of indicator. For the comparison of quantitative data between groups, the t-test or Wilcoxon rank sum test will be used according to the data distribution. For the comparison of categorical data between groups, the data will be analyzed by chi-square test or exact probability method (if the chi-square test is not applicable). And the grade data was analyzed by Wilcoxon rank sum test or CMH test.
Clinical diagnostic index calculation According to the true positive (TP), false negative (FN), true negative (TN), and false positive (FP), the results of SLNs pathological examination and all lymph node pathological examination results will be compared. The comparison results will be plotted as a four-grid table to calculate sensitivity, false negative rate, and negative predictive value, respectively.
Chi-square test or exact probability method (if the chi-square test is not applicable) will be used to compare the clinical diagnosis value of SLNs biopsy of endometrial cancer patients with injection of carbon nanoparticles (CNP) or combined injection of CNP and indocyanine green(ICG).
Chi-square test or exact probability method (if the chi-square test is not applicable) will be used to analyze the clinic-pathological factors affecting the detection rate of SLNs.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100044
- Recruiting
- Peking University People's Hospital
-
Contact:
- Jianliu Wang, Professor
-
Principal Investigator:
- Xiaoping Wan, Professor
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of early cervical cancer (FIGO IA1 with LVSI (+) to IIA).
- Decide to receive extra-fascial/sub-extensive/extensive hysterectomy, pelvic with or without aortic lymph node resection
- Agree to conduct the study and sign an informed consent form
Exclusion Criteria:
- Diagnosis of cervical cancer in FIGO IIB stage and above
- History of previous pelvic or inguinal lymphadenectomy or other history of surgery affecting the uterine lymphatic drainage
- Other history of pelvic or abdominal malignant tumors in the past 5 years
- Intolerable for surgery due to severe comorbidities
- During a period of pregnancy
- Allergic to the tracer
- Diagnosis of uncontrolled epilepsy, central nervous system disease or mental disorder, with the judgment from the investigator that the above diseases would affect clinical research compliance.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Undergoing sentinel lymph node biopsy
This group of patients will undergo sentinel lymph node biopsy.
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Negative Predictive Value
Time Frame: Through study completion, an average of 2 years
|
Sentinel lymph node detection is defined as at least one lymph node is found in a patient.
Sentinel lymph node negative is defined as no sentinel lymph node detected.
True negative is defined as no metastasis found in both sentinel lymph nodes (SLNs) and non-SLNs.
Negative predictive value is defined as the proportion of true negative patients to SLNs negative patients in patients with sentinel lymph nodes detected, which means patients without SLNs detected won't be included in the calculation.
|
Through study completion, an average of 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SLNs detection rate
Time Frame: Through study completion, an average of 2 years
|
Sentinel lymph node detection is defined as at least one lymph node is found in a patient.
The detection rate is the proportion of the patients with SLNs detected in all enrolled patients.
|
Through study completion, an average of 2 years
|
Sensitivity
Time Frame: Through study completion, an average of 2 years
|
Sensitivity is defined as the proportion of the SLNs positive patients in patients with SLNs or non-SLNs lymphatic metastasis (among the patients with SLNs detected)
|
Through study completion, an average of 2 years
|
False negative rate
Time Frame: Through study completion, an average of 2 years
|
False negative is defined as no metastasis found in SLNs while metastasis found in non-SLNs.
False negative rate is defined as the proportion of the false negative patients in the patients with SLNs or non-SLNs lymphatic metastasis(among the patients with SLNs detected)
|
Through study completion, an average of 2 years
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Jianliu Wang, Professor, Peking University People's Hospital
Publications and helpful links
General Publications
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210. Epub 2014 Oct 9.
- Holloway RW, Abu-Rustum NR, Backes FJ, Boggess JF, Gotlieb WH, Jeffrey Lowery W, Rossi EC, Tanner EJ, Wolsky RJ. Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations. Gynecol Oncol. 2017 Aug;146(2):405-415. doi: 10.1016/j.ygyno.2017.05.027. Epub 2017 May 28.
- Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer. 1987 Oct 15;60(8 Suppl):2035-41. doi: 10.1002/1097-0142(19901015)60:8+3.0.co;2-8.
- NCCN Guidelines Version 1. 2018. Cervical Cancer [EB/OL]. [2018-02-10]. http://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf.
- Lu Y, Wei JY, Yao DS, Pan ZM, Yao Y. Application of carbon nanoparticles in laparoscopic sentinel lymph node detection in patients with early-stage cervical cancer. PLoS One. 2017 Sep 5;12(9):e0183834. doi: 10.1371/journal.pone.0183834. eCollection 2017.
- Liang SC, Wang ZQ, Wang JL. [Clinical analysis of 76 cases of sentinel lymph node detection in cervical cancer and endometrial cancer]. Zhonghua Fu Chan Ke Za Zhi. 2017 Sep 25;52(9):605-611. doi: 10.3760/cma.j.issn.0529-567X.2017.09.006. Chinese.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018PHD003-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Uterine Cervical Neoplasms
-
Huazhong University of Science and TechnologyChongqing University Cancer Hospital; Peking University People's Hospital; Qilu... and other collaboratorsRecruitingCervical Cancer | Uterine Cervical Cancer | Uterine Cervical NeoplasmChina
-
Huazhong University of Science and TechnologyUnknownCervical Cancer | Uterine Cervical Cancer | Uterine Cervical NeoplasmChina
-
Huazhong University of Science and TechnologyQilu Hospital of Shandong University; Third Military Medical University; Women... and other collaboratorsRecruitingCervical Cancer | Uterine Cervical Cancer | Uterine Cervical NeoplasmChina
-
University of AarhusRecruitingUterine Cervical Neoplasm | Mass Screening | Uterine Cervical Disease | Uterine NeoplasmDenmark
-
Huazhong University of Science and TechnologyZhejiang University; Wuhan Central HospitalUnknownCervical Cancer | Uterine Cervical Neoplasms | Uterine Cervical CancerChina
-
Washington University School of MedicineTerminatedCervical Cancer | Uterine Cervical Neoplasms | Uterine Cervical CancerUnited States
-
Huazhong University of Science and TechnologyShandong University; Zhejiang UniversityCompletedCervical Cancer | Uterine Cervical Neoplasms | Uterine Cervical CancerChina
-
Center Eugene MarquisCompleted
-
University Hospitals Cleveland Medical CenterCompletedUterine Cervical Dysplasia | Uterine Cervical Cancer | Uterine Cervical Neoplasia | Uterine Cervical Intraepithelial Neoplasia
-
Siriwan Tangjitgamol, MDPrince of Songkla University; National Research Council of Thailand; Chiang Mai... and other collaboratorsUnknownUterine Cervical CancerThailand
Clinical Trials on sentinel lymph node biopsy
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...CompletedBreast Neoplasm Female
-
Gangnam Severance HospitalCompletedNeoadjuvant Chemotherapy | Micrometastases
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingConjunctival Melanoma | Porocarcinoma | Ocular Surface Squamous Neoplasia | Merkel Cell Carcinoma, Unspecified | Ocular Sebaceous Carcinoma | Ocular Basal Cell CarcinomaItaly
-
Bulent Ecevit UniversityRecruiting
-
Professor Fernando Figueira Integral Medicine InstituteCompletedUterine Cervical Neoplasms | Uterine NeoplasmsBrazil
-
The Christie NHS Foundation TrustWithdrawnSquamous Cell Carcinoma of the Anus
-
Jewish General HospitalMcGill University Health Centre/Research Institute of the McGill University...RecruitingSentinel Lymph Node | Cutaneous Squamous Cell CarcinomaCanada
-
Cliniques universitaires Saint-Luc- Université...Unknown
-
Peking University People's HospitalSun Yat-sen University; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaboratorsUnknown
-
Washington University School of MedicineTerminated